[{"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "fullTimeEmployees": 50000, "auditRisk": 2, "boardRisk": 5, "compensationRisk": 3, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 172.13, "open": 172.7, "dayLow": 169.59, "dayHigh": 172.93, "regularMarketPreviousClose": 172.13, "regularMarketOpen": 172.7, "regularMarketDayLow": 169.59, "regularMarketDayHigh": 172.93, "dividendRate": 6.2, "dividendYield": 0.0364, "exDividendDate": 1721001600, "payoutRatio": 1.7827001, "fiveYearAvgDividendYield": 4.37, "beta": 0.582, "trailingPE": 50.71131, "forwardPE": 14.128524, "volume": 12308051, "regularMarketVolume": 12308051, "averageVolume": 5292501, "averageVolume10days": 5101590, "averageDailyVolume10Day": 5101590, "bidSize": 800, "askSize": 1000, "marketCap": 300886589440, "fiftyTwoWeekLow": 130.96, "fiftyTwoWeekHigh": 182.89, "priceToSalesTrailing12Months": 5.530699, "fiftyDayAverage": 163.9016, "twoHundredDayAverage": 160.03716, "trailingAnnualDividendRate": 6.06, "trailingAnnualDividendYield": 0.03520595, "currency": "USD", "enterpriseValue": 357216223232, "profitMargins": 0.11016, "floatShares": 1762300728, "sharesOutstanding": 1765869952, "sharesShort": 15927790, "sharesShortPriorMonth": 13536080, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.009, "heldPercentInsiders": 0.00105, "heldPercentInstitutions": 0.72739, "shortRatio": 3.04, "shortPercentOfFloat": 0.009, "bookValue": 4.535, "priceToBook": 37.572216, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "earningsQuarterlyGrowth": 4.728, "netIncomeToCommon": 5951000064, "trailingEps": 3.36, "forwardEps": 12.06, "pegRatio": 2.46, "enterpriseToRevenue": 6.566, "enterpriseToEbitda": 13.678, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ABBV", "underlyingSymbol": "ABBV", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "firstTradeDateEpochUtc": 1357137000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "gmtOffSetMilliseconds": -14400000, "currentPrice": 170.39, "targetHighPrice": 207.0, "targetLowPrice": 170.0, "targetMeanPrice": 184.08, "targetMedianPrice": 185.11, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 25, "totalCash": 18069000192, "totalCashPerShare": 10.232, "ebitda": 26115999744, "totalDebt": 74358996992, "quickRatio": 0.723, "currentRatio": 0.936, "totalRevenue": 54402998272, "debtToEquity": 924.059, "revenuePerShare": 30.775, "returnOnAssets": 0.07705, "returnOnEquity": 0.56244, "freeCashflow": 23611500544, "operatingCashflow": 22685999104, "earningsGrowth": 4.964, "revenueGrowth": 0.007, "grossMargins": 0.69174004, "ebitdaMargins": 0.48005, "operatingMargins": 0.28294, "financialCurrency": "USD", "trailingPegRatio": 0.4467, "__fetch_time": "2024-06-24"}]